Author:
Gruntmanis Ugis,Fordan Steve,Ghayee Hans K.,Abdullah Shuaib M.,See Raphael,Ayers Colby R.,McGuire Darren K.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism
Reference36 articles.
1. Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351:1106–1118
2. Avandia (2007) Highlights of prescribing information [package insert]. Glaxo Smith Kline, pp 1–42
3. Actos (2007) Prescribing information. Takeda Pharmaceutical Company, pp 1–4
4. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL (2005) Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146:1226–1235
5. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B (2007) Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148:2669–2680
Cited by
46 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献